153 related articles for article (PubMed ID: 18260361)
1. [Tumor inhibitory factors in urologic malignancies].
Uemura H
Hinyokika Kiyo; 2008 Jan; 54(1):49-52. PubMed ID: 18260361
[TBL] [Abstract][Full Text] [Related]
2. [Molecular changes in development and progression of urothelial carcinoma].
Hartmann A
Verh Dtsch Ges Pathol; 2003; 87():172-84. PubMed ID: 16888910
[TBL] [Abstract][Full Text] [Related]
3. Tumour suppressor genes in urinary tract oncology.
Brewster SF; Gingell JC; Brown KW
Br J Urol; 1992 Dec; 70(6):585-90. PubMed ID: 1336697
[No Abstract] [Full Text] [Related]
4. Gene therapy approaches in urologic oncology.
Vieweg J; Gilboa E
Surg Oncol Clin N Am; 1995 Apr; 4(2):203-18. PubMed ID: 7796281
[TBL] [Abstract][Full Text] [Related]
5. The molecular pathology of urological malignancies.
Dorkin TJ; Robson CN; Neal DE
J Pathol; 1997 Dec; 183(4):380-7. PubMed ID: 9496253
[TBL] [Abstract][Full Text] [Related]
6. Alternative splicing of fibroblast growth factor receptor 3 produces a secreted isoform that inhibits fibroblast growth factor-induced proliferation and is repressed in urothelial carcinoma cell lines.
Tomlinson DC; L'Hôte CG; Kennedy W; Pitt E; Knowles MA
Cancer Res; 2005 Nov; 65(22):10441-9. PubMed ID: 16288035
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of disease: angiogenesis in urologic malignancies.
Charlesworth PJ; Harris AL
Nat Clin Pract Urol; 2006 Mar; 3(3):157-69. PubMed ID: 16528288
[TBL] [Abstract][Full Text] [Related]
8. Molecular alterations associated with bladder cancer initiation and progression.
Cordon-Cardo C
Scand J Urol Nephrol Suppl; 2008 Sep; (218):154-65. PubMed ID: 18815930
[TBL] [Abstract][Full Text] [Related]
9. Nucleic acid-based marker approaches to urologic cancers.
Veltri RW; Makarov DV
Urol Oncol; 2006; 24(6):510-27. PubMed ID: 17138133
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of Disease: genetic and epigenetic alterations that drive bladder cancer.
Wolff EM; Liang G; Jones PA
Nat Clin Pract Urol; 2005 Oct; 2(10):502-10. PubMed ID: 16474624
[TBL] [Abstract][Full Text] [Related]
11. Molecular therapy in urologic oncology.
Froehner M; Hakenberg OW; Wirth MP
Urol Int; 2007; 79(1):1-7. PubMed ID: 17627159
[TBL] [Abstract][Full Text] [Related]
12. Clinical applications of recent molecular advances in urologic malignancies: no longer chasing a "mirage"?
Netto GJ
Adv Anat Pathol; 2013 May; 20(3):175-203. PubMed ID: 23574774
[TBL] [Abstract][Full Text] [Related]
13. Expression of vascular endothelial growth factor, receptor KDR and p53 protein in transitional cell carcinoma of the bladder.
Liu L; Zhu D; Gao R; Guo H
Urol Int; 2008; 81(1):72-6. PubMed ID: 18645275
[TBL] [Abstract][Full Text] [Related]
14. Inherited urologic malignant disorders: nursing implications.
Middelton L; Lessick M
Urol Nurs; 2003 Feb; 23(1):15-8, 23-9; quiz 30. PubMed ID: 12677717
[TBL] [Abstract][Full Text] [Related]
15. Molecular and cytogenetic events in urologic tumors.
Klein EA; Fair WR; Chaganti RS
Semin Urol; 1988 Feb; 6(1):2-21. PubMed ID: 2838875
[No Abstract] [Full Text] [Related]
16. The role of methylation in urological tumours.
van der Heijden AG
Arch Esp Urol; 2013 Jun; 66(5):432-9. PubMed ID: 23793761
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor (EGFR) expression in prostatic adenocarcinoma after hormonal therapy: a fluorescence in situ hybridization and immunohistochemical analysis.
Marks RA; Zhang S; Montironi R; McCarthy RP; MacLennan GT; Lopez-Beltran A; Jiang Z; Zhou H; Zheng S; Davidson DD; Baldridge LA; Cheng L
Prostate; 2008 Jun; 68(9):919-23. PubMed ID: 18409189
[TBL] [Abstract][Full Text] [Related]
18. Surveillance of urothelial carcinoma: stage and grade migration, 1993-2005 and survival trends, 1993-2000.
David KA; Mallin K; Milowsky MI; Ritchey J; Carroll PR; Nanus DM
Cancer; 2009 Apr; 115(7):1435-47. PubMed ID: 19215030
[TBL] [Abstract][Full Text] [Related]
19. Potential use of RNA interference as therapeutic strategy in urologic cancer.
Green WJ; James PA; Ratan HL
Urology; 2011 Sep; 78(3):500-4. PubMed ID: 21741681
[No Abstract] [Full Text] [Related]
20. Antineoplastic effect of proliferation signal inhibitors: from biology to clinical application.
Bertoni E; Salvadori M
J Nephrol; 2009; 22(4):457-62. PubMed ID: 19662600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
